Leukemia Clinical Trials

Showing 2181-2200 of 5,235 trials

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

NCT03054909

This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.

FIGO Stage III and IV Ovarian CancerFIGO Stage III and IV Fallopian Tube CancerFIGO Stage III Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota7 participantsStarted Sep 2017

Minneapolis, Minnesota, United States

TERMINATEDPhase 1

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

NCT03690154

This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors include lung cancer, breast cancer, prostate cancer, kidney cancer, colorectal cancer, melanoma and sarcoma. The purpose of this research study is to evaluate the safety of the investigational study drug, FN-1501, at different dose levels. FN-1501 has not previously been given to human subjects. It is intended for the treatment in this study of patients with advanced solid tumor cancers. This study will determine the effects, good and/or bad, on patients' cancer. The main objective of this study is to define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of FN-1501. The MTD is the highest dose a person can take without having bad side effects, and the RP2D will be the dose of FN-1501 used in future studies.

Advanced CancerSolid TumorsAcute Myeloid Leukemia Refractory+1 more

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.67 participantsStarted Jul 2018

Fairway, Kansas, United States • Detroit, Michigan, United States • Malvern, Victoria, Australia

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Related Searches

Advanced Multimodal Wireless Vital Signs Monitoring for Patients With Asthma and Anaphylaxis

One Session Vs Staged Management of Calcular Obstructive Jaundice

Predictors of Aortic Root Dilatation in Tetralogy of Fallot Patients

Same-Day PrEP Initiation and Sexual Health for Transgender Women

BrUOG 390: Neoadjuvant Treatment With Talazoparib

The Choice of Treatment Methods and Efficacy of LABC

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Evaluate the Efficacy of the OITcontrol Application.

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot -

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia

Double/Single Balloon Enteroscopy Stiffening Wire RCT

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer